CSIMarket
 
Vertex Pharmaceuticals Inc  (NASDAQ: VRTX)
 
Price: $546.1200 $-11.84 -2.122%
Day's High: $556.4080200195312 Week Perf: 0.29 %
Day's Low: $ 544.48 30 Day Perf: 12.83 %
Volume (M): 801,784 52 Wk High: $ 560.25
Volume (M$): $ 0 52 Wk Avg: $454.45
Open: $548.71 52 Wk Low: $374.17



 Market Capitalization (Millions $) 139,370
 Shares Outstanding (Millions) 255
 Employees 405
 Revenues (TTM) (Millions $) 12,587
 Net Income (TTM) (Millions $) 4,405
 Cash Flow (TTM) (Millions $) 523
 Capital Exp. (TTM) (Millions $) 497

Business Description


Company Profile: Vertex Pharmaceuticals Inc.

Company Overview
Vertex Pharmaceuticals Inc. is a leading biotechnology company committed to discovering, developing, and commercializing innovative medicines targeting serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex has established itself as a pioneer in the field of cystic fibrosis and is expanding its reach into other therapeutic areas.

Specialization in Cystic Fibrosis
Vertex Pharmaceuticals has made a significant impact in the treatment of cystic fibrosis, a genetic disorder that primarily affects the lungs and digestive system. The companys first breakthrough drug, Kalydeco (ivacaftor), received approval in 2012 and is recognized as the first medication that addresses the underlying cause of cystic fibrosis by targeting specific genetic mutations. Following this, Vertex launched additional therapies, including Orkambi (lumacaftor/ivacaftor) and Symdeko (tezacaftor/ivacaftor), which have transformed the lives of many patients living with this condition.

Broader Therapeutic Focus
In addition to its advancements in cystic fibrosis treatments, Vertex Pharmaceuticals is actively exploring other therapeutic domains, including sickle cell disease, beta thalassemia, and pain management. The companys research and development initiatives are primarily centered around small molecules and gene therapies, focusing on the development of precision medicines that aim to directly target the root causes of diseases.

Commitment to Corporate Social Responsibility
Vertex is not only dedicated to medical innovation but also prioritizes corporate social responsibility. The company emphasizes environmental sustainability by implementing practices such as energy conservation, recycling, and sustainable building initiatives to minimize its carbon footprint. Furthermore, Vertex supports patient advocacy organizations and has established various programs designed to enhance patient access to its medications.

Conclusion
Vertex Pharmaceuticals Inc. stands at the forefront of biotechnology, driven by its innovative research, a talented team of scientists and clinicians, and a robust commitment to patients and the community. With its unwavering focus on developing groundbreaking therapies for serious diseases, Vertex is well-positioned to continue making a profound impact in the healthcare landscape.


   Company Address: 50 Northern Avenue Boston 2210 MA
   Company Phone Number: 341-6100   Stock Exchange / Ticker: NASDAQ VRTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMRN        2.88% 
JNJ        2.68% 
MRK        1.33% 
OGN        0.15% 
PFE        1.75% 
TEVA   -0.22%    
• View Complete Report
   



Business Update

Vertex Pharmaceuticals Makes Strides in Innovative Therapies Promising Developments and Strategic Agreements Propel t...

Published Mon, Oct 20 2025 9:48 AM UTC

As Vertex Pharmaceuticals continues its path of innovation and alignment with cutting-edge medical advancements, the company recently announced significant progress across its development program for povetacicept. This investigational recombinant fusion protein therapeutic is positioned as a dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation induci...

Business Update

Vertex Pharmaceuticals Sustains Strong Financial Growth Through 2025 via Strategic Product Launches and Clinica...

Published Tue, Oct 7 2025 9:51 AM UTC

: Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has exhibited impressive financial growth throughout 2025, underpinned by strategic product launches and ongoing advancements in clinical programs. This article provides an in-depth analysis of Vertex s financial performance for the first three quarters of 2025, highlighting notable achievements and laying out expectations...

Business Update

s with the recent approval from the European Commission for the expanded label of its cystic fibrosis treatment, KAFT...

Published Thu, Sep 18 2025 4:08 PM UTC

Vertex Pharmaceuticals (Nasdaq: VRTX), a leader in innovative therapies for serious diseases, is making strides in improving patient access to life-saving treatments. In a significant announcement from its London headquarters, the company confirmed a new reimbursement agreement with the Italian Medicines Agency (AIFA) for its groundbreaking CRISPR/Cas9 gene-edited therapy, C...

Business Update

Vertex Pharmaceuticals Pioneering New Horizons in Cystic Fibrosis Treatment and Financial Performance,

Published Tue, Aug 5 2025 5:39 AM UTC

Vertex Pharmaceuticals: Driving Innovation and Growth in Cystic Fibrosis Treatments In a compelling display of innovation and market responsiveness, Vertex Pharmaceuticals (Nasdaq: VRTX) has recently reported its second-quarter financial results for 2025 while also celebrating a significant regulatory achievement. The company has established itself as a leader in the biotech...

Business Update

Vertex Pharmaceuticals Faces Mixed Quarter Strategic Expansion Amidst Earnings Challenges

Published Tue, May 6 2025 7:48 AM UTC

In the recent financial landscape, Vertex Pharmaceuticals Inc. has reported its first-quarter results for 2025, which showcased a combination of resilience and challenges. Although shares have demonstrated an overall outperformance compared to the broader market year-to-date, the latest results have stirred investor apprehension.Despite the company s stocks experiencing a do...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 31.84
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 11.07
Price to Sales (Expected) -
Price to Book 6.88
PEG (TTM) 1.43

Financial Strength Current
Quick Ratio 1.99
Working Capital Ratio 3.19
Leverage Ratio (MRQ) 0.35
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 17.15 $
Revenues (TTM) 49.32 $
Cash Flow (TTM) 2.05 $
Cash 30.77 $
Book Value 79.34 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 31,079,506
Net Income per Employee (TTM) 10,877,037
Receivable Turnover Ratio (TTM) 6.19
Inventory Turnover Ratio (TTM) 1.03
Asset Turnover Ratio (TTM) 0.48

Profitability Ratios Current
Gross Margin (MRQ) 85.33 %
Operating Margin (MRQ) 37.4 %
Net Margin (MRQ) 32.99 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 16.48 %

Management Effectiveness Current
Return On Assets (TTM) 16.88 %
Return On Investment (TTM) 19.97 %
Return On Equity (TTM) 23.31 %
Dividend Yield -
Pay out Ratio (TTM) -



Vertex Pharmaceuticals Inc's Segments
Product    189.59 % of total Revenue
ALYFTREK    29.93 % of total Revenue
TRIKAFTA/KAFTRIO    145.53 % of total Revenue
Manufactured Product, Other    8.19 % of total Revenue
Cystic Fibrosis Products    183.66 % of total Revenue
CASGEVY    3.58 % of total Revenue
JOURNAVX    2.36 % of total Revenue
United States    114.95 % of total Revenue
Europe    57.82 % of total Revenue
Other Countries Outside of the United States and Europe    16.82 % of total Revenue
Non-US    74.64 % of total Revenue
Pharmaceuticals    189.59 % of total Revenue

  Vertex Pharmaceuticals Inc Outlook

On August 2 2024 the Vertex Pharmaceuticals Inc provided following guidance

Vertex Pharmaceuticals Incorporated has announced its financial results for the second quarter of 2024, concluding on June 30. Following this robust performance, the company has revised its full-year revenue projections upward to an impressive range of $10.65 billion to $10.85 billion.

In the report, Reshma Kewalramani, M.D., who serves as the Chief Executive Officer and President of Vertex, highlighted the company's strong quarter marked by significant revenue growth and exemplary execution across various facets of the business. This positive momentum has prompted the company to adjust its revenue expectations for the year, reflecting their confidence in future performance.

Vertex continues ...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.